Evidence map›Paper›PMID 30776949›Full record

ArticleJournal of the American Heart Association2019

Diabetes Mellitus-Related All-Cause and Cardiovascular Mortality in a National Cohort of Adults.

Sridharan Raghavan, Jason L Vassy, Yuk-Lam Ho, Rebecca J Song, David R Gagnon, Kelly Cho, Peter W F Wilson, Lawrence S Phillips

Registry-linked trialOpen access · goldAbstract readMulticenter Study
In one paragraph

Article in Journal of the American Heart Association, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03170362 (PRIME Care), which is not on this map. Cited by 300 papers, 14 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
300citing papers in PubMed, 14 pooled it
31.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03170362 nacompletednot on this map

PRIME Care (PRecision Medicine In MEntal Health Care)

TypeinterventionalSponsorVA Office of Research and DevelopmentRan2017 to 2022Enrolled1,944ConditionsMajor DepressionArmsPharmacogenetic Test
3 · Its place in the literature

Who cites it

300 citing papers in PubMed, 14 syntheses or guidelines pooled it, 564 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Thiazolidinediones for people with chronic kidney disease and diabetes.The Cochrane database of systematic reviews · 2025
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Effect ofInternational journal of molecular sciences · 2024
    Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Article

240 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Sridharan Raghavan1 Department of Veterans Affairs Eastern Colorado Healthcare System Aurora CO.
Jason L Vassy4 Department of Veterans Affairs Boston Healthcare System Boston MA.
Yuk-Lam Ho4 Department of Veterans Affairs Boston Healthcare System Boston MA.
Rebecca J Song4 Department of Veterans Affairs Boston Healthcare System Boston MA.
David R Gagnon4 Department of Veterans Affairs Boston Healthcare System Boston MA.
Kelly Cho4 Department of Veterans Affairs Boston Healthcare System Boston MA.
Peter W F Wilson7 Department of Veterans Affairs Atlanta Medical Center Atlanta GA.
Lawrence S Phillips7 Department of Veterans Affairs Atlanta Medical Center Atlanta GA.
VA Boston Healthcare System · USEmory University · USBoston University · USHarvard University · USOutcomes Research Consortium · US

Funding

Glycemia Reduction Approaches in Diabetes: A comparative effectiveness studyU01DK098246 · NIDDK · GEORGE WASHINGTON UNIVERSITY · PI KRAUSE-STEINRAUF, HEIDI, LACHIN, JOHN M · 2012 to 2022
$238.9M
Translational Research Core - Engagement and Behavior ChangeP30DK111024 · NIDDK · EMORY UNIVERSITY · PI Mohammed Kumail Ali · 2016 to 2026
$13.4M
Screening for IGT: Glucose Challenge vs Predictive ModelR18DK066204 · NIDDK · EMORY UNIVERSITY · PI PHILLIPS, LAWRENCE S · 2004 to 2007
$2.9M
Prevention of Cystic Fibrosis DiabetesR01FD003527 · FDA · EMORY UNIVERSITY · PI STECENKO, ARLENE A · 2009 to 2015
$908k
Vitamin D for Type 2 Diabetes (D2D trial)U34DK091958 · NIDDK · TUFTS MEDICAL CENTER · PI PITTAS, ANASTASSIOS G · 2011 to 2012
$792k
Reach, Outcomes and System Impacts of the VA's National Weight Loss Program, MOVER21DK099716 · NIDDK · EMORY UNIVERSITY · PI PHILLIPS, LAWRENCE S · 2014 to 2015
$321k
CSRD VA I01 CX001025CSRD VA IK2 CX001262FDA HHS R01 FD003527NIDDK NIH HHS P30 DK111024NIDDK NIH HHS R18 DK066204NIDDK NIH HHS R21 DK099716NIDDK NIH HHS U01 DK098246NIDDK NIH HHS U34 DK091958
6 · The paper itself

Abstract

Background Diabetes mellitus is a risk factor for cardiovascular disease ( CVD ) and has been associated with 2- to 4-fold higher mortality. Diabetes mellitus-related mortality has not been reassessed in individuals receiving routine care in the United States in the contemporary era of CVD risk reduction. Methods and Results We retrospectively studied 963 648 adults receiving care in the US Veterans Affairs Healthcare System from 2002 to 2014; mean follow-up was 8 years. We estimated associations of diabetes mellitus status and hemoglobin A1c (HbA1c) with all-cause and CVD mortality using covariate-adjusted incidence rates and multivariable Cox proportional hazards regression. Of participants, 34% had diabetes mellitus. Compared with nondiabetic individuals, patients with diabetes mellitus had 7.0 (95% CI , 6.7-7.4) and 3.5 (95% CI, 3.3-3.7) deaths/1000-person-years higher all-cause and CVD mortality, respectively. The age-, sex-, race-, and ethnicity-adjusted hazard ratio for diabetes mellitus-related mortality was 1.29 (95% CI, 1.28-1.31), and declined with adjustment for CVD risk factors (hazard ratio, 1.18 [95% CI, 1.16-1.19]) and glycemia (hazard ratio, 1.03 [95% CI, 1.02-1.05]). Among individuals with diabetes mellitus, CVD mortality increased as HbA1c exceeded 7% (hazard ratios, 1.11 [95% CI, 1.08-1.14], 1.25 [95% CI, 1.22-1.29], and 1.52 [95% CI, 1.48-1.56] for HbA1c 7%-7.9%, 8%-8.9%, and ≥9%, respectively, relative to HbA1c 6%-6.9%). HbA1c 6% to 6.9% was associated with the lowest mortality risk irrespective of CVD history or age. Conclusions Diabetes mellitus remains significantly associated with all-cause and CVD mortality, although diabetes mellitus-related excess mortality is lower in the contemporary era than previously. We observed a gradient of mortality risk with increasing HbA1c >6% to 6.9%, suggesting HbA1c remains an informative predictor of outcomes even if causality cannot be inferred.

Indexed as

Population SurveillanceAgedBlood GlucoseCardiovascular DiseasesCause of DeathDiabetes Mellitus, Type 2FemaleFollow-Up StudiesGlycated HemoglobinHumansMaleMiddle AgedRetrospective StudiesRisk AssessmentRisk FactorsSurvival RateBlood GlucoseGlycated Hemoglobincardiovascular diseasediabetes mellitusmortality

Identifiers

PMID30776949
PMCPMC6405678
OpenAlexW2916269741

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.